Antibody Kinetics and Response to Routine Vaccinations in Infants Born to Women Who Received an Investigational Trivalent Group B Streptococcus Polysaccharide CRM 197 -Conjugate Vaccine During Pregnancy조사 3가 그룹 B 연쇄상구균 다당류 CRM 197 -임신 중 접합 백신을 받은 여성에게서 태어난 영아의 항체 동역학 및 정기 예방 접종에 대한 반응Articles and Commentaries Published on 2017-12-012022-09-06 Journal: Clinical Infectious Diseases: An Official Publicat [Category] Communicable Disease, [키워드] age antenatal vaccination antibody antibody level antibody levels Birth capsular clinical clinically Combination detectable Diphtheria diphtheria toxoid disease dosage dosages dose during pregnancy elicited enrolled geometric mean geometric mean concentration group group B Streptococcus conjugate vaccine groups Haemophilus influenzae Haemophilus influenzae type b immune response immune responses Infant Infants invasive investigated Kinetics Maternal mother not affect pediatric Placebo placebo group pneumococcal pneumococcal vaccination Pregnancy Randomized receive Received recipients Registration response Result routine routine immunization serotype serotype-specific serotypes significantly higher single-center study Streptococcus Tetanus the placebo group timepoint transferred trivalent vaccination Vaccine were assessed women [DOI] 10.1093/cid/cix666 PMC 바로가기 [Article Type] Articles and Commentaries
Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial남아프리카 공화국의 유아 및 유아에 대한 비경구 P2-VP8-P[8] 서브유닛 로타바이러스 백신의 안전성 및 면역원성: 무작위, 이중 맹검, 위약 대조 시험Articles Published on 2017-05-052022-09-06 Journal: The Lancet. Infectious Diseases [Category] Communicable Disease, [키워드] 95% CI adjusted adverse event adverse events African approach assigned benefit block Block randomisation Cohort computer-generated different dose different doses dose dose-escalation doses double-blind eligible Endpoint enrolled finding FIVE followed by foundation Frequency funding geometric mean geometric mean titre geometric mean titres groups healthy highest HIV-uninfected homologous hospital IgA IgG IgG seroresponse immunogenic immunogenicity Infant Infants injection Injections Laboratory live oral rotavirus vaccines Local Melinda Gate Melinda Gates Mild neutralising antibody neutralising antibody seroresponse neutralising antibody seroresponses nine non-replicating rotavirus vaccine occurred offer oral rotavirus vaccine oral vaccines parent Parenteral parents participant Placebo placebo group placebo-controlled placebo-controlled trial primary immunogenicity randomisation randomised reaction receiving reduced Registered Research rotavirus rotavirus disease rotavirus vaccination rotavirus vaccine Safety safety analysis safety endpoint Serious Adverse Event Serious Adverse Events Serum IgA seroresponse Serum IgA seroresponses Seven severity South South Africa subunit Subunit vaccine systemic reaction systemic reactions the placebo group those receiving placebo Treatment Trial trivalent vaccination Vaccine was done was used [DOI] 10.1016/S1473-3099(17)30242-6 PMC 바로가기 [Article Type] Articles
Feasibility of a randomized controlled trial to assess treatment of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection in Saudi Arabia: a survey of physiciansResearch Article Published on 2016-07-122022-10-28 Journal: BMC Anesthesiology [Category] Coronavirus, MERS, [키워드] Blood Care clinical trial convalescent convalescent plasma Convalescent plasma therapy coronavirus Critical care Critically ill determine diagnose domain feasibility high mortality rate ICU ICUs include indicated Infection involved ISARIC Kingdom Laboratory majority MERS-CoV MERS-CoV-infected patient Middle East Middle East respiratory syndrome coronavirus (MERS-CoV) MOST participated patients physician Physicians Placebo questionnaire Randomized controlled trial Randomized controlled trials RCT RCTs recovered patients reported Research respiratory respiratory pathogen responsible Result Saudi Arabia specific treatment supplementary material Treatment while [DOI] 10.1186/s12871-016-0198-x PMC 바로가기 [Article Type] Research Article
Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trialHIV-1에 감염된 건강한 성인에서 후보 결핵 백신 MVA85A의 안전성, 면역원성 및 효능: 무작위, 위약 대조, 2상 시험Articles Published on 2015-03-012022-09-06 Journal: The Lancet. Respiratory Medicine [Category] Communicable Disease, [키워드] 1:1 95% CI absence active tuberculosis adverse event Antigen antigen 85A antigen 85A-specific T-cell response antiretroviral Antiretroviral therapy assigned assist baseline baseline CD4 block blocks booster Cape CD4 count CD4 counts Cell clinical defined detect detectable Developing disease double-blind effective Efficacy eligible Eligible participants enrolled enrolment European Evidence evidence of expressing finding first vaccination foundation funding gold greater Group allocation had no healthy HIV-1 HIV-1 infection immunogenic immunogenicity include increased risk Infection injection intradermal injections investigators isoniazid isoniazid prophylaxis Laboratory latent tuberculosis latent tuberculosis infection M tuberculosis Measures Melinda Gate Melinda Gates modified vaccinia virus MVA85A Mycobacterium tuberculosis nine no evidence of Nurses occurred outcome participant partnership peaked per-protocol analysis per-protocol population Phase 2 phase 2 trial Placebo placebo group placebo-controlled positive Potential Prophylaxis protocol QuantiFERON QuantiFERON-TB Gold In-Tube randomisation randomised Randomly receive receiving Registered reported Safe Safety safety analysis second vaccination secondary Secondary outcomes sequence Serious Adverse Event Serious Adverse Events significant increase South Africa stratified subset T-cell Response the placebo group therapy town Treatment Trial Tuberculosis tuberculosis disease tuberculosis vaccine undetectable vaccination Vaccine vaccine efficacy vaccine-induced immune response Viral Viral load Wellcome Trust were assessed [DOI] 10.1016/S2213-2600(15)00037-5 PMC 바로가기 [Article Type] Articles
A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virusClinical Trial Published on 2010-05-112022-10-06 Journal: Proceedings of the National Academy of Sciences of [Category] 진단, [키워드] acquisition Administered Adult Adults Analysis antibody antiviral activity Antiviral effect assays clinical evidence concentrations decrease different double-blind Effectiveness enrolled exhibiting Factors healthy subject Human increase in independent Infected infected children Infection intranasal mechanism mRNA multiple logistic regression murine model nasal nasal washe nucleocapsid number of infected PCR Placebo placebo-controlled study placebo-controlled trial Proinflammatory cytokine proportion Protein protein expression Randomized recipient recipients representing respiratory syncytial virus RNA RSV RSV infection safety profile saline placebo significantly lower siRNA subjects tested therapeutic Therapeutic approach therapy treat uninfected unique viral culture was measured wild-type [DOI] 10.1073/pnas.0912186107 PMC 바로가기 [Article Type] Clinical Trial